Impact Of Increasing Pneumonia Prevalence On The Acute Respiratory Distress Syndrome (ARDS) Market: Core Growth Enabler in the Acute Respiratory Distress Syndrome (ARDS) Market, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Acute Respiratory Distress Syndrome (ARDS) Industry Market Size Be by 2025?
The market size for acute respiratory distress syndrome (ARDS) has experienced accelerated growth in the recent past. The market is expected to expand from $1.29 billion in 2024 to $1.42 billion in 2025, boasting a compound annual growth rate (CAGR) of 10.4%. This growth in the historical interval is linked to the evolution in critical care medicine, an aging populace, enhancements in pulmonary rehabilitation, and the rise of multidisciplinary care teams.

What's the Long-Term Growth Forecast for the Acute Respiratory Distress Syndrome (ARDS) Market Size Through 2029?
The market size for acute respiratory distress syndrome (ARDS) is projected to experience swift expansion in the upcoming years, ballooning to a value of $2.17 billion by the year 2029 with a compound annual growth rate (CAGR) of 11.1%. The predicted surge during this forecast period can be traced back to worldwide preparation in the healthcare industry, development of vaccines, efficient management of communicable diseases, incorporation of telemedicine and remote patient monitoring, as well as patient-focused healthcare models. Key trends to watch out for during this forecast period include the advent of artificial lung devices, bespoke ventilation strategies, protection-focused lung ventilation, and drug therapies tailored for specific ARDS subtypes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-respiratory-distress-syndrome-ards-global-market-report

What Are the Key Growth Drivers Fueling the Acute Respiratory Distress Syndrome (ARDS) Market Expansion?
The acute respiratory distress syndrome (ARDS) market is predicted to grow due to the escalating occurrence of pneumonia. Pneumonia, a lung infection that can result in fluid or pus filling the lungs' alveoli, triggers an inflammatory response in the lungs. This response leads to an increase in blood vessel permeability and thus fluid leakage into the alveoli. The resulted fluid buildup hampers the exchange of oxygen and carbon dioxide, leading to respiratory discomfort. As an example, in November 2023, the Centre for Tropical Medicine and Global Health, a UK-based healthcare research leader, reported a significant rise in pneumonia cases in Kenya, reaching 793,864 in 2022-2023, up from 477,186 cases in 2020-2021. Consequently, the growing prevalence of pneumonia is likely to spur the growth of the acute respiratory distress syndrome (ARDS) market. A significant inducer of the Acute Respiratory Distress Syndrome (ARDS) market's growth is projected to be the surge in respiratory illnesses. These medical conditions that can affect the lung and airways make breathing difficult for the sufferers. The upward trend in respiratory illnesses, like COVID-19, fuels the acute respiratory distress syndrome (ARDS) market. This trend is expected to surge the demand for ARDS treatments and therapies, encouraging market expansion. As an example, in November 2023, the Bureau of Labor Statistics, a US government agency, reported that the illness rate among private industry employers rose to 45.2 cases per 10,000 full-time equivalent (FTE) workers in 2022, from 37.7 cases in 2021. The primary reason for this rise were the increased incidence of respiratory illnesses, which soared from 27.8 cases per 10,000 FTE workers in 2021 to 35.8 cases in 2022. Therefore, the increasing number of respiratory illnesses is a significant driver of the acute respiratory distress syndrome (ARDS) market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp

What Are the Key Trends Driving Acute Respiratory Distress Syndrome (ARDS) Market Growth?
In a bid to maintain their market positions in the acute respiratory distress syndrome (ARDS) sector, key corporations are concentrating on creating innovative drugs and supplements such as Aviptadil and HSP90 inhibitors among others. Aviptadil, a manufactured vasoactive intestinal peptide (VIP), selectively attaches to receptors on lung alveolar type II cells. For instance, in November 2022, Aviptadil was unveiled as a treatment for ARDS by Zuventus Healthcare Ltd., a pharmaceutical manufacturer based in India. Aviptadil, a vasoactive intestinal peptide supplement, enhances breathing and reduces the mortality rate among ARDS patients. This is achieved through the drug's capacity to shield and regenerate Type-2 Pneumocytes, revive Type-1 Pneumocytes, boost surfactant synthesis, and inhibit IL-6 (interleukin 6) and tumor necrosis factor (TNF)-alpha.

How Is the Acute Respiratory Distress Syndrome (ARDS) Market Segmented?
The acute respiratory distress syndrome (ARDS) market covered in this report is segmented -

1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users

Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp

Which Companies Are Leading the Charge in Acute Respiratory Distress Syndrome (ARDS) Market Innovation?
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline PLC, Medtronic PLC, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, ResMed Inc., Smiths Medical Inc., Dräger Safety AG & Co. KGaA., Getinge AB, Mallinckrodt PLC, Masimo Corporation, United Therapeutics Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Zuventus Healthcare Ltd., Windtree Therapeutics Inc., Faron Pharmaceuticals Oy, AcelRx Pharmaceuticals Inc.

Which Regions Are Leading the Global Acute Respiratory Distress Syndrome (ARDS) Market in Revenue?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe - +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.